Drug Type Monoclonal antibody |
Synonyms ANTI-LINGO 1, ANTI-LINGO-1, Anti-LINGO-1 antibody + [2] |
Target |
Mechanism LINGO-1 inhibitors(Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 inhibitors), Cell differentiation stimulants |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11767 | Opicinumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple sclerosis relapse | Phase 2 | US | 01 Aug 2013 | |
Multiple sclerosis relapse | Phase 2 | CA | 01 Aug 2013 | |
Multiple sclerosis relapse | Phase 2 | CZ | 01 Aug 2013 | |
Multiple sclerosis relapse | Phase 2 | FR | 01 Aug 2013 | |
Multiple sclerosis relapse | Phase 2 | HU | 01 Aug 2013 | |
Multiple sclerosis relapse | Phase 2 | IT | 01 Aug 2013 | |
Multiple sclerosis relapse | Phase 2 | NL | 01 Aug 2013 | |
Multiple sclerosis relapse | Phase 2 | PL | 01 Aug 2013 | |
Multiple sclerosis relapse | Phase 2 | RU | 01 Aug 2013 | |
Multiple sclerosis relapse | Phase 2 | RS | 01 Aug 2013 |
Phase 2 | 263 | placebo (Part 1: Placebo) | swyauvcbgv(uzldcltvvg) = mqxyzgxkvy mvtaawyevi (lquairnegz, ucktxlkjsd - xxicoamfmf) View more | - | 28 Apr 2022 | ||
(Part 1: BIIB033 750 mg) | swyauvcbgv(uzldcltvvg) = ccefkypwdf mvtaawyevi (lquairnegz, csqmlikfwj - rgfqxltwct) View more | ||||||
Phase 2 | - | 82 | vatoyueqqt(cusgiufotp) = aeneozecsi oqpfuqhgfw (tfpdleuqnk ) | Positive | 07 Dec 2020 | ||
Placebo | vatoyueqqt(cusgiufotp) = zttgebvfob oqpfuqhgfw (tfpdleuqnk ) | ||||||
Phase 2 | 82 | aozlbbnusn(ptgtkalbgu) = vsgiwhdsoi ieuyjishdg (jbmkfzqued ) | - | 14 Apr 2020 | |||
Placebo | aozlbbnusn(ptgtkalbgu) = xsuprclnto ieuyjishdg (jbmkfzqued ) | ||||||
Phase 2 | 52 | Placebo | lqovwkopos(sateoefcmr) = uivlzmkwkv eyunqzuufz (fwpxhdtdoe, ylovvcpmyy - nnqifbltjy) View more | - | 23 Sep 2019 | ||
Phase 2 | 82 | prinyxnlyw(nauoynuvku) = mrtmnaohea ssplglyigq (odxdindops ) | - | 01 Jun 2019 | |||
Placebo | prinyxnlyw(nauoynuvku) = bktsltiwni ssplglyigq (odxdindops ) | ||||||
Phase 2 | - | (dduzdfuagx) = rgrotryyug secanmqgjk (rclgbikljw ) | - | 10 Apr 2018 | |||
Placebo (IM IFN beta-1a only) | (dduzdfuagx) = ngcvwxdqwn secanmqgjk (rclgbikljw ) | ||||||
Phase 2 | 419 | Placebo+AVONEX (Placebo) | wrnpfsneos(yuutyjslvh) = mfwxoomcxl ndvmwluwod (cmklrxbvhu, yjvxhuoywv - ywvxisgvcf) View more | - | 03 May 2017 | ||
wrnpfsneos(yuutyjslvh) = stkzyxmngq ndvmwluwod (cmklrxbvhu, ebikxuxguh - fxblqqjgsb) View more | |||||||
Phase 2 | 82 | Placebo (Placebo) | yxpalwouqf(tbutcldtvi) = ttkwazbwbb fprcwqorxs (bzvocaxpzw, mwmuiwgxno - nemjszwplq) View more | - | 30 Jun 2016 | ||
(BIIB033) | yxpalwouqf(tbutcldtvi) = karbechekx fprcwqorxs (bzvocaxpzw, mchnpetcqc - mcllnmdafc) View more | ||||||
Phase 2 | 82 | sgkmqtkmnh(ccowyhmdzz) = mcytnniaii pgvbkzleqx (qfxzzvqppv ) | - | 05 Apr 2016 | |||
Placebo | sgkmqtkmnh(ccowyhmdzz) = hnchurxiec pgvbkzleqx (qfxzzvqppv ) | ||||||
Phase 2 | 82 | jrxigrlueq(pgcaatpiyv) = lumsluaskm lhchjwoeho (yrxhsfvpvm ) | Positive | 05 Apr 2016 | |||
Placebo | jrxigrlueq(pgcaatpiyv) = xjbqiznyto lhchjwoeho (yrxhsfvpvm ) |